Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.

Author: Kajilkis Turisar
Country: Cape Verde
Language: English (Spanish)
Genre: Marketing
Published (Last): 25 June 2016
Pages: 19
PDF File Size: 8.91 Mb
ePub File Size: 14.41 Mb
ISBN: 554-4-31237-416-2
Downloads: 58381
Price: Free* [*Free Regsitration Required]
Uploader: Bakora

Severe Because of the potential for torsade de pointes TdPuse of macimorelin with dofetilide is contraindicated. Dofetilide is metabolized to a small extent by CYP3A4, and inhibitors of the CYP3A4 isoenzyme, such as mifepristone, could increase systemic dofetilide exposure, further increasing the risk for QT prolongation.

Telithromycin is associated with QT prolongation and torsades de pointes TdP. Total clearance of dofetilide is decreased and plasma concentration is increased in proportion to the paackage in creatinine clearance associated with renal disease. Metabolites are formed by N-dealkylation and N-oxidation.

The increase in QT interval observed on the ECG is a result of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles. Severe QT prolongation and torsade de pointes TdP have been reported in patients treated with dofeetilide. Prolongation of the QTc interval and ventricular arrhythmias have been reported in patients treated with ivosidenib.

Dofetilide – GlobalRPH

Severe Hypokalemia or hypomagnesemia may occur with administration of potassium-depleting drugs such as loop diuretics and thiazide diuretics, increasing the potential for dofetilide-induced torsade de pointes. Minor Coadministration of dofetilide with inducers of CYP3A4, such as nevirapine, may increase the metabolism of dofetilide.


Because increases in the QT interval and the risk of ventricular arrhythmias are directly related to plasma concentrations of dofetilide, it is critical that the dose of dofetilide be pcakage based on calculated CrCl.

Your Name Your name is required. Chlorpromazine is specifically associated with an established risk of QT prolongation and TdP; case reports have included patients receiving therapeutic doses of chlorpromazine. Therefore, sparfloxacin is contraindicated in patients receiving these drugs or other drugs that can cause QT prolongation, such as class III antiarrhythmics.

Alcoholism, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes. Severe Pentamidine has been associated with QT prolongation.

Mefloquine alone has not been reported to cause QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Based on these findings, the manufacturer of dofetilide contraindicates the concomitant use of hydrochlorothiazide alone or in combination with other drugs such as triamterene ; these findings can be explained both by an increase in the plasma concentration of dofetilide and a reduction in the serum potassium concentration.

Electrolyte imbalances should be corrected prior to initiation of therapy. Dialysis, renal disease, renal failure, renal impairment. The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is generally not recommended due to the potential risk for ventricular tachycardia, including TdP and monomorphic ventricular tachycardia.

The concomitant use of dronedarone with other drugs that prolong the QTc may induce TdP and is contraindicated. Osimertinib causes concentration dependent prolongation of the Dofefilide interval at recommended dosing.

QT prolongation has occurred with both drugs, and dofetilide is also dofetliide with a well-established risk for TdP.


There was a problem providing the content you requested

Severe Because of the potential for Torsade de pointes TdPconcurrent use of arsenic trioxide and dofetilide is contraindicated. Mifepristone has been associated with dose-dependent prolongation of the QT interval. TdP and complete atrioventricular block have been reported. Severe QT prolongation has occurred during therapeutic use of atomoxetine and following overdose. Major Dofetilide should be co-administered with tenofovir, PMPA with caution since both drugs are actively secreted via cationic secretion and could compete for common renal tubular transport systems.

Azithromycin has been associated with cases of QT prolongation and TdP, reported during the post-marketing period.

We’re strengthening digital security to protect you.

Major Coadministration of lamotrigine and dofetilide is not recommended. Severe Sparfloxacin is associated pacmage an established risk for QT prolongation and torsades de pointes.

Severe Arrhythmias, sinus bradycardia, and conduction disturbances have occurred during octreotide therapy warranting more cautious monitoring during octreotide administration in higher risk patients with cardiac disease. Potassium levels should be within the normal range prior and during administration of dofetilide.

Limited data indicate that QT prolongation is possible with apomorphine administration; the change in QTc interval is not significant in most patients receiving dosages within the manufacturer’s guidelines. Severe Coadministration of inotuzumab ozogamicin with dofetilide is contraindicated due to the potential for additive QT interval prolongation and risk of dofetilidr de pointes TdP.